Forklaringen på dette var en lavere ophørsfrekvens i forsøgsbehandlingen pga. lavere sygdomsprogression hos patienter, som fik lenalidomid/ dexamethason (39, 7%) end hos patienter, som fik placebo/ dexamethason (70, 4%).
The difference was accounted for by a lower rate of discontinuation from study treatment due to lower progression of disease in patients exposed to lenalidomide/dexamethasone (39.7%) than in placebo/dexamethasone patients (70.4%).